Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
出版年份 2022 全文链接
标题
Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 14, Pages 7889
出版商
MDPI AG
发表日期
2022-07-18
DOI
10.3390/ijms23147889
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
- (2022) Zhi Qi et al. Nature Communications
- Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results From a Phase II Cohort
- (2022) D.S. Hong et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
- (2022) Barbara Burtness et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
- (2022) Simon Eschweiler et al. NATURE
- Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer
- (2022) Lachlan McDowell et al. Frontiers in Oncology
- Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pre-treated recurrent and metastatic head and neck cancer
- (2021) Tien-Hua Chen et al. Journal of the Chinese Medical Association
- Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
- (2021) Shiwen Peng et al. mBio
- Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
- (2021) Christine H. Chung et al. Cancers
- Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
- (2021) Carlos Gomez‐Roca et al. CTS-Clinical and Translational Science
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
- (2021) Alan L. Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
- (2021) Assuntina G Sacco et al. LANCET ONCOLOGY
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
- (2021) Robert L Coleman et al. LANCET ONCOLOGY
- Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
- (2021) Dan P Zandberg et al. Journal for ImmunoTherapy of Cancer
- DNA Methylation and HPV-Associated Head and Neck Cancer
- (2021) Takuya Nakagawa et al. Microorganisms
- Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- (2021) Grégoire Marret et al. INVESTIGATIONAL NEW DRUGS
- PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
- (2021) Matteo Caforio et al. Cancers
- Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
- (2021) Aini Hyytiäinen et al. Frontiers in Oncology
- Tisotumab Vedotin: First Approval
- (2021) Anthony Markham DRUGS
- Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers
- (2021) David E. Symer et al. GENOME RESEARCH
- Phase 1/2a, open‐label, multicenter study of RM ‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma
- (2021) David M. Cognetti et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
- (2021) Christine Chung et al. Journal for ImmunoTherapy of Cancer
- Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers
- (2021) Jade Z. Zhou et al. Cancers
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma
- (2020) V. Sambandam et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.
- (2020) Faye M. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.
- (2020) Alan Loh Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients
- (2020) Kunal H. Bhatt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
- (2020) Xu-Shan Sun et al. LANCET ONCOLOGY
- Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
- (2020) Hye Ryun Kim et al. BRITISH JOURNAL OF CANCER
- Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration
- (2020) Gioia Di Credico et al. BRITISH JOURNAL OF CANCER
- Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
- (2020) Olga Bednova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
- (2020) Cinzia Solinas et al. Translational Oncology
- Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics
- (2020) Junfang Lyu et al. Nature Communications
- The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
- (2020) Xin-wei Qiao et al. Frontiers in Immunology
- Personalized Cancer Vaccination in Head and Neck Cancer
- (2020) Hirofumi Shibata et al. CANCER SCIENCE
- Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides
- (2020) Jamie V. Shiah et al. MOLECULAR CANCER THERAPEUTICS
- Head and neck squamous cell carcinoma
- (2020) Daniel E. Johnson et al. Nature Reviews Disease Primers
- NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma
- (2020) Pooja A. Shah et al. Cells
- PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
- (2019) Vaishnavi Sambandam et al. CLINICAL CANCER RESEARCH
- Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and Demographic Burden of HPV-associated Oropharyngeal Head and Neck Cancers in the United States
- (2019) Brandon A Mahal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Clinical update on head and neck cancer: molecular biology and ongoing challenges
- (2019) Elham Alsahafi et al. Cell Death & Disease
- Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors
- (2019) Rodrigo Barbosa de Aguiar et al. Frontiers in Immunology
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
- (2019) Stacey L. Doran et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
- (2019) Panagiota Economopoulou et al. Frontiers in Oncology
- 1120PDBuparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial
- (2019) J Fayette et al. ANNALS OF ONCOLOGY
- 1210PPhase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
- (2019) C Le Tourneau et al. ANNALS OF ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
- (2019) Y Guo et al. ANNALS OF ONCOLOGY
- Epstein–Barr virus molecular epidemiology and variants identification in head and neck squamous cell carcinoma
- (2019) Mohammad Hadi Karbalaie Niya et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
- (2019) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- (2019) Martin Schuler et al. LANCET ONCOLOGY
- PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
- (2019) Franziska E. Marquard et al. BIOCHEMICAL PHARMACOLOGY
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- (2019) Cristina P. Rodriguez et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
- (2018) Andreas Wicki et al. EUROPEAN JOURNAL OF CANCER
- STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
- (2018) Yu-Lin Su et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
- (2018) Emanuele Giurisato et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Head and Neck Cancer by Vaccination
- (2018) Chuan Wang et al. Frontiers in Immunology
- Abstract 2977: PI3K/mTOR pathway inhibition induces Aurora B mediated cell death inNOTCH1mutant head and neck squamous (HNSCC) cells
- (2018) Vaishnavi Sambandam et al. CANCER RESEARCH
- A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
- (2018) Sophie Papa et al. JOURNAL OF CLINICAL ONCOLOGY
- Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers
- (2018) Mushfiq H. Shaikh et al. ORAL ONCOLOGY
- Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
- (2018) Steven F. Gameiro et al. OncoImmunology
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- 1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
- (2018) E E W Cohen et al. ANNALS OF ONCOLOGY
- Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
- (2018) Maura L. Gillison et al. GENOME RESEARCH
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
- (2018) Hisham Mehanna et al. LANCET
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene
- (2018) Xueqian Gong et al. Cancer Discovery
- Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
- (2018) Matthew G. Oser et al. Cancer Discovery
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
- (2017) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Denis Soulières et al. LANCET ONCOLOGY
- Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors
- (2017) David Martin et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils
- (2017) Taru Ilmarinen et al. ORAL ONCOLOGY
- Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
- (2017) Aviram Mizrachi et al. Nature Communications
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- Trial Watch: Adoptively transferred cells for anticancer immunotherapy
- (2017) Carole Fournier et al. OncoImmunology
- Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Athanassios Argiris et al. Frontiers in Oncology
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
- (2016) Xavier Castellsagué et al. JNCI-Journal of the National Cancer Institute
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
- (2016) Koos Koole et al. Molecular Diagnosis & Therapy
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
- (2016) Uddalak Bharadwaj et al. Oncotarget
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
- (2016) Xavier Castellsagué et al. JNCI-Journal of the National Cancer Institute
- Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
- (2015) T. Dogruluk et al. CANCER RESEARCH
- Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
- (2015) L. M. Draper et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
- (2015) Tim F Greten et al. GUT
- Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
- (2015) Yassine Lalami et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma
- (2015) Maura L. Gillison et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
- (2015) Juan Madoz-Gúrpide et al. Journal of Translational Medicine
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1 Phosphorylation
- (2015) G. J. Cerniglia et al. MOLECULAR CANCER THERAPEUTICS
- Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
- (2015) B. Gabrielli et al. MOLECULAR CANCER THERAPEUTICS
- A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2015) Antonio Jimeno et al. ORAL ONCOLOGY
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2014) A. Jimeno et al. ANNALS OF ONCOLOGY
- A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
- (2014) T. Y. Seiwert et al. ANNALS OF ONCOLOGY
- Head and Neck Cancer: Global Burden and Regional Trends in India
- (2014) Anupam Mishra et al. Asian Pacific Journal of Cancer Prevention
- High-risk HPV types and head and neck cancer
- (2014) Dominique S. Michaud et al. INTERNATIONAL JOURNAL OF CANCER
- Harnessing Massively Parallel Sequencing in Personalized Head and Neck Oncology
- (2014) M. Jessri et al. JOURNAL OF DENTAL RESEARCH
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
- (2014) T. Mazumdar et al. MOLECULAR CANCER THERAPEUTICS
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Next generation sequencing and its application in deciphering head and neck cancer
- (2014) Maryam Jessri et al. ORAL ONCOLOGY
- Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air Pollution
- (2014) Ian Chi Kei Wong et al. Chinese Journal of Cancer
- Th17 Cells in Cancer: The Ultimate Identity Crisis
- (2014) Stefanie R. Bailey et al. Frontiers in Immunology
- Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models
- (2013) Sarah Elizabeth Wheeler et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
- (2013) David Vasquez-Dunddel et al. JOURNAL OF CLINICAL INVESTIGATION
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
- (2013) Friederike Göke et al. MODERN PATHOLOGY
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
- (2013) Stephen B. Keysar et al. Molecular Oncology
- A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
- (2013) Sewanti Limaye et al. ORAL ONCOLOGY
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma†
- (2012) C. Xue et al. ANNALS OF ONCOLOGY
- Lessons learned from next-generation sequencing in head and neck cancer
- (2012) Myriam Loyo et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Enhancement of radiation response with bevacizumab
- (2012) Tien Hoang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
- (2012) Jian Yang et al. STEM CELLS
- Human papillomavirus, smoking, and head and neck cancer
- (2011) Parul Sinha et al. AMERICAN JOURNAL OF OTOLARYNGOLOGY
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
- (2011) Makoto Mitsunaga et al. NATURE MEDICINE
- Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
- (2011) N. Agrawal et al. SCIENCE
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis
- (2010) Lydia Durant et al. IMMUNITY
- HPV-associated head and neck cancer: a virus-related cancer epidemic
- (2010) Shanthi Marur et al. LANCET ONCOLOGY
- Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin
- (2009) D. Liu et al. CANCER RESEARCH
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Simon W. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
- (2008) Jan. B. Vermorken et al. CANCER
- Gene-environment interaction in tobacco-related cancers
- (2008) E. Taioli CARCINOGENESIS
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
- (2008) Pingyan Cheng et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT3: An Important Regulator of Multiple Cytokine Functions
- (2008) Stanislaw M. Stepkowski et al. TRANSPLANTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started